It is basically a contingency table created with PROC FREQ. In its simplest form, it would have one dimension as treatment group and the other the outcome of interest.
if you work for drug development and are talking about the drug efficacy then this is not a SAS question. you may want to ask your colleagues about what efficacy endpoints your drug will have.
SAS Innovate 2025: Save the Date
SAS Innovate 2025 is scheduled for May 6-9 in Orlando, FL. Sign up to be first to learn about the agenda and registration!